Physician profile
Madelyn King
NPI 1811342124
$3,382.08
in general payments reported to CMS, 2019-2025
20 companies · $442 in 2025
The $442 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $168 · 2021: $423 · 2022: $791 · 2023: $439 · 2024: $722 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.98 |
| Education | $105.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.54 | 2019-2025 | |
| Janssen Biotech, INC. | $978.23 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Galderma Laboratories, L.P. | $231.09 | 2023-2025 | Dysport |
| Amgen INC. | $174.63 | 2019-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $113.16 | 2021-2022 | |
| Pfizer INC. | $104.67 | 2019-2022 | |
| Ucb, INC. | $92.80 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $85.14 | 2020-2024 | Ebglyss |
| Leo Pharma INC. | $82.32 | 2021-2024 | Adbry |
| Incyte Corporation | $70.73 | 2021-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $68.22 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $66.33 | 2023 | Tremfya |
| Arcutis Biotherapeutics, INC. | $55.71 | 2023-2025 | Zoryve |
| Genzyme Corporation | $53.61 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $37.96 | 2022-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.64 | 2023 | Spevigo |
| Organon LLC | $23.04 | 2025 | Vtama |
| Dermavant Sciences, INC. | $17.02 | 2024 | Vtama |
| Almirall LLC | $14.07 | 2024 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $13.17 | 2023 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madelyn King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.